Risk of new AIDS diseases in people on triple therapy

Lancet

Volumn 353, Issue 9151, 1999, Pages 463-

  Miller, Veronica ^c   Staszewski, Schlomo ^c   Nisius, Gabriella ^c   Cozzi Lepri, Alessandro ^c   Sabin, Caroline ^c   Phillips, Andrew N ^a,b  

^a Schwerpunkt Endokrinologie   (Germany)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOVIRIDE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RISK;

EID: 0001673402     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)04954-X     Document Type: Article

References (2)

1. Hammer S.M., Squires K.E., Hughes M.D.et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 37:1997;725-733.
2. Staszewski S, Miller V, Sabin C, et al. Determinants of substantial CD4 count increases in response to antiviral therapy. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy 24-27 June 1998 (abstr 93).